Wave Life Sciences (WVE)

• Market cap: $1.07B
• 1 day: -3.47%
• 5 days: -5.05%
• 1 month: 8.76%
• 3 months: -32.33%
• 6 months: -48.29%
• Year to date: -47.82%
• 1 year: 7.25%
• 5 years: -31.66%
• 10 years: -56.56%
• Sector: Healthcare
• Industry: Biotechnology

About: WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Employees: 288

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

164% more call options, than puts

Call options by funds: $4.91M | Put options by funds: $1.86M

62% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 21

61% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 51

7% more funds holding

Funds holding: 182 [Q4 2024] → 194 (+12) [Q1 2025]

1.21% more ownership

Funds ownership: 84.32% [Q4 2024] → 85.53% (+1.21%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 4 (+0) [Q1 2025]

33% less capital invested

Capital invested by funds: $1.59B [Q4 2024] → $1.06B (-$530M) [Q1 2025]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $10 44% upside
• Avg. target: $15.33 121% upside
• High target: $22 217% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Raymond James Michael Freeman	101% upside $14	Outperform Assumed	11 Jun 2025
Cantor Fitzgerald Steven Seedhouse	44% upside $10	Overweight Initiated	29 Apr 2025
HC Wainwright & Co. Andrew Fein	217% upside $22	Buy Reiterated	26 Mar 2025